Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
Protein & Cell
;
(12): 573-589, 2017.
Article
in English
| WPRIM
| ID: wpr-756986
ABSTRACT
Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment that has recently been undergoing rapid development. However, there are still some major challenges, including precise tumor targeting to avoid off-target or "on-target/off-tumor" toxicity, adequate T cell infiltration and migration to solid tumors and T cell proliferation and persistence across the physical and biochemical barriers of solid tumors. In this review, we focus on the primary challenges and strategies to design safe and effective CAR T cells, including using novel cutting-edge technologies for CAR and vector designs to increase both the safety and efficacy, further T cell modification to overcome the tumor-associated immune suppression, and using gene editing technologies to generate universal CAR T cells. All these efforts promote the development and evolution of CAR T cell therapy and move toward our ultimate goal-curing cancer with high safety, high efficacy, and low cost.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Therapeutics
/
Transplantation
/
Recombinant Fusion Proteins
/
Lymphocyte Activation
/
Receptors, Antigen, T-Cell
/
T-Lymphocytes
/
Signal Transduction
/
Gene Expression
/
Cell Movement
Limits:
Humans
Language:
English
Journal:
Protein & Cell
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS